Neuronetics, Inc. announced that Francis X. Brown III’s appointment as interim principal financial and accounting officer ended on August 11, 2026, without any dispute or disagreement with management. Concurrently, the Board appointed Nir Naor to serve as the Company’s principal financial and accounting officer effective August 12, 2026. Mr. Naor, who was previously named Executive Vice President, Chief Financial Officer, and Treasurer in July 2026, also assumed the title of Corporate Secretary. He received no new compensation for these additional roles. Neuronetics, Inc. operates in the medical device industry, developing neuromodulation therapies.

Neuronetics reported second quarter 2026 total revenue of $41.6 million, a 9.1% increase from the prior year period. Greenbrook clinic revenue grew 16.8% to $26.9 million, while NeuroStar device revenue declined 2.7% to $14.7 million. The company achieved positive adjusted EBITDA of $0.3 million compared to a loss of $5.6 million in the prior year quarter and reported a net loss of $3.4 million versus $10.1 million previously. Management updated its full-year 2026 revenue guidance to $160–$164 million and operating expense guidance to exclude stock-based compensation, projecting adjusted operating expenses between $91 million and $96 million. The company also appointed Nir Naor as CFO and Rob Greene as SVP of Sales. Neuronetics operates in the interventional mental health industry, providing transcranial magnetic stimulation technology and direct patient care through its Greenbrook clinic network.

Neuronetics, Inc. announced that its board of directors promoted Cory Anderson from Senior Vice President, Chief Technology Officer to Executive Vice President, General Manager of Greenbrook, effective July 1, 2026. As part of this promotion, Mr. Anderson's annual base salary will increase to $425,000, and his target discretionary annual cash bonus will increase to 45% of his base salary. Mr. Anderson brings over 25 years of medical device leadership experience, having previously held various R&D and clinical roles within the company and leadership positions at Sebacia, The Innovation Factory, and Accuitive Medical Ventures. Neuronetics, Inc. is a medical technology company focused on neuromodulation.